Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ACAD

Acadia Pharmaceuticals Inc

Dec 20 • 04:00PM ET

16.87

Dollar change +0.14
Percentage change 0.84	%

Healthcare • Biotechnology • USA • NASD

Peers: NBIX BIIB VRTX INCY BMRN ALNY IONS REGN GILD AMGN

| Held by: IWM VTI XBI VB FBT VXF VBK IBB IWO SCHA

Scroll to Statements

Index	RUT	P/E	21.84	EPS (ttm)	0.77	Insider Own	1.26%	Shs Outstand	166.35M	Perf Week	-2.26%
Market Cap	2.83B	Forward P/E	22.17	EPS next Y	0.76	Insider Trans	-3.46%	Shs Float	164.30M	Perf Month	3.69%
Income	128.51M	PEG	-	EPS next Q	0.22	Inst Own	93.77%	Short Float	6.03%	Perf Quarter	3.56%
Sales	929.24M	P/S	3.05	EPS this Y	293.22%	Inst Trans	-4.76%	Short Ratio	6.66	Perf Half Y	6.23%
Book/sh	3.47	P/B	4.86	EPS next Y	6.41%	ROA	15.97%	Short Interest	9.91M	Perf Year	-41.93%
Cash/sh	3.37	P/C	5.01	EPS next 5Y	-	ROE	27.36%	52W Range	14.15 - 32.59	Perf YTD	-46.12%
Dividend Est.	-	P/FCF	13.97	EPS past 5Y	28.03%	ROI	20.81%	52W High	-48.24%	Beta	0.39
Dividend TTM	-	Quick Ratio	2.11	Sales past 5Y	27.73%	Gross Margin	91.61%	52W Low	19.22%	ATR (14)	0.74
Dividend Ex-Date	-	Current Ratio	2.29	EPS Y/Y TTM	185.18%	Oper. Margin	12.08%	RSI (14)	49.60	Volatility	4.46% 4.25%
Employees	598	Debt/Eq	0.09	Sales Y/Y TTM	47.06%	Profit Margin	13.83%	Recom	1.79	Target Price	25.11
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	149.70%	Payout	-	Rel Volume	3.32	Prev Close	16.73
Sales Surprise	0.63%	EPS Surprise	44.82%	Sales Q/Q	18.28%	Earnings	Nov 06 AMC	Avg Volume	1.49M	Price	16.87
SMA20	-1.02%	SMA50	4.03%	SMA200	2.15%	Trades		Volume	4,937,928	Change	0.84%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-07-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$28 → $20
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$31
Mar-12-24	Reiterated	Needham	Buy	$36 → $32
Mar-12-24	Downgrade	Mizuho	Buy → Neutral	$39 → $25
Jan-30-24	Initiated	Robert W. Baird	Outperform	$40
Jan-24-24	Upgrade	Needham	Hold → Buy	$37
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$31 → $40
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold	$25
Dec-13-23	Initiated	Citigroup	Buy	$38
Dec-12-23	Initiated	Deutsche Bank	Buy	$25
Nov-06-23	Upgrade	Mizuho	Neutral → Buy	$20 → $35
Oct-17-23	Initiated	UBS	Buy	$33
Oct-10-23	Upgrade	JP Morgan	Neutral → Overweight	$29 → $32
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$22
Nov-04-22	Downgrade	Goldman	Neutral → Sell	$15 → $12
Nov-01-22	Initiated	Loop Capital	Hold	$17
Aug-08-22	Downgrade	Citigroup	Buy → Neutral	$19 → $15
Aug-05-22	Downgrade	Citigroup	Buy → Neutral	$19 → $15
Jun-21-22	Downgrade	Jefferies	Buy → Underperform	$25 → $10

Show Previous Ratings

Dec-19-24 04:05PM	Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 (Business Wire)
Dec-16-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-11-24 04:05PM	Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million (Business Wire)
Dec-09-24 09:00AM	Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer (Business Wire) +8.56%
Dec-03-24 09:50AM	Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term (Zacks)
08:32AM	Loading…
08:32AM	Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options (Zacks)
Nov-27-24 07:06AM	Acadia signs agreement with Saniona to commercialise SAN711 (Pharmaceutical Technology)
Nov-26-24 04:05PM	Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711 (Business Wire)
Nov-21-24 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Nov-15-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-12-24 09:50AM	Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock (Zacks)
Nov-07-24 06:00AM	ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) +8.93%
Nov-06-24 05:15PM	Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates (Zacks) +5.27%
04:13PM	Acadia: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview (Business Wire)
04:05PM	Loading…
Nov-05-24 04:05PM	Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million (Business Wire)
Oct-31-24 02:22PM	ACADIA Pharmaceuticals Inc (ACAD): Worst-Performing Growth Stock in 2024 (Insider Monkey)
Oct-17-24 06:41PM	Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024 (Business Wire)
07:28AM	Health Canada approves Acadias DAYBUE for Rett syndrome (Pharmaceutical Technology)
Oct-16-24 04:07PM	Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE (trofinetide) for the Treatment of Rett Syndrome (Business Wire)
Oct-08-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-26-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-23-24 04:15PM	Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals (Business Wire)
Aug-29-24 08:30AM	Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options (Zacks)
Aug-28-24 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Aug-14-24 08:04AM	Ryan Reynolds Announces More to Parkinsons Campaign (Business Wire)
Aug-07-24 04:30PM	Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire) -19.52%
04:14PM	Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains' (Investor's Business Daily)
08:16AM	Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues (Zacks)
Aug-06-24 05:45PM	Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue Estimates (Zacks)
04:42PM	Loading…
04:42PM	Acadia: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview (Business Wire)
Jul-30-24 10:01AM	Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-24-24 04:05PM	Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024 (Business Wire)
Jul-18-24 09:04AM	Clinical Data from Open-Label Extension LILAC-1 and LILAC-2 Studies Evaluating Long-Term Safety and Efficacy of DAYBUE (trofinetide) in Patients with Rett Syndrome Published in Med (Business Wire)
Jul-16-24 10:28AM	Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe (Zacks)
Jun-21-24 12:24PM	Why Is ACADIA Pharmaceuticals Inc (ACAD) One of the Best Debt Free Halal Stocks According to Hedge Funds? (Insider Monkey)
10:53AM	7 Best Halal Stocks To Buy Now (Debt Free) (Insider Monkey)
Jun-18-24 09:04AM	Acadia Pharmaceuticals Presents DAYBUE (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting (Business Wire)
Jun-07-24 11:30AM	Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue? (Zacks)
May-29-24 10:01AM	3 Sorry Pharma Stocks to Sell in May While You Still Can (InvestorPlace)
May-17-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-15-24 09:05AM	Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome (Business Wire)
May-10-24 01:15PM	ACADIA Pharmaceuticals Q1 2024 Earnings: Solid Growth with New Product Launches (GuruFocus.com)
11:20AM	UBS Cuts Price Target on ACADIA Pharmaceuticals to $25 From $27, Keeps Buy Rating (MT Newswires)
10:01AM	Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating (MT Newswires)
May-09-24 04:58PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire) -11.21%
03:29PM	ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:07AM	Stifel Adjusts Price Target on ACADIA Pharmaceuticals to $21 From $26, Keeps Hold Rating (MT Newswires)
05:59AM	Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss (Zacks)
03:37AM	ACADIA Pharmaceuticals Inc (ACAD) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue ... (GuruFocus.com)
May-08-24 08:57PM	ACAD Stock Earnings: ACADIA Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:15PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates (Zacks)
04:15PM	Acadia: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview (Business Wire)
May-04-24 02:27AM	Insider Sale: CEO Stephen Davis Sells Shares of ACADIA Pharmaceuticals Inc (ACAD) (GuruFocus.com)
May-01-24 10:01AM	Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-30-24 12:17PM	UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating (MT Newswires)
Apr-29-24 04:16PM	Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship (Business Wire)
Apr-24-24 04:05PM	Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024 (Business Wire)
Apr-22-24 09:04AM	Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada (Business Wire)
Apr-20-24 09:15AM	5 Best Healthcare Stocks to Buy Under $20 (Insider Monkey)
Apr-19-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-17-24 04:05PM	Acadia Pharmaceuticals Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting (Business Wire)
Apr-11-24 02:10PM	3 Pharma Stocks to Sell in April Before They Crash & Burn (InvestorPlace)
Apr-10-24 01:28AM	ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares (GuruFocus.com)
Apr-02-24 04:05PM	Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development (Business Wire)
Apr-01-24 04:05PM	Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-28-24 11:30AM	Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report? (Zacks)
02:00AM	ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares (GuruFocus.com)
Mar-20-24 01:31PM	Billionaire Steve Cohen and Insiders are Buying These 5 Stocks (Insider Monkey)
Mar-15-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-14-24 06:49PM	3 Pharma Stocks to Sell in March Before They Crash & Burn (InvestorPlace)
Mar-13-24 04:05PM	Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day (Business Wire)
Mar-12-24 04:08PM	Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study (Investor's Business Daily) -17.20%
03:05PM	Acadia Pharmaceuticals Stock Sinks After Schizophrenia Drug Study Falls Short (Investopedia)
11:06AM	Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails (Zacks)
09:30AM	Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today? (InvestorPlace)
07:43AM	5 Things to Know Before the Stock Market Opens (Investopedia)
Mar-11-24 04:46PM	UPDATE 2-Acadia to stop trials of antipsychotic drug after it fails schizophrenia study (Reuters)
04:13PM	Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study (Reuters)
04:05PM	Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia (Business Wire)
Feb-29-24 09:05AM	Acadia Pharmaceuticals to Participate in TD Cowens 44th Annual Health Care Conference on March 6, 2024 (Business Wire)
08:44AM	ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 04:05PM	Acadia Stock Dives As Unexpected Seasonality Rocks Its Most High-Profile Launch (Investor's Business Daily) -9.92%
09:12AM	Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down (Zacks)
Feb-27-24 05:20PM	Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Zacks)
04:56PM	ACADIA Pharmaceuticals Inc. Reports Strong Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
04:27PM	Acadia: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview (Business Wire)
Feb-22-24 08:16PM	ACADIA Pharmaceuticals Inc. Investors: Please contact the Portnoy Law Firm to recover your losses (GlobeNewswire)
Feb-21-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-20-24 10:00AM	Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-13-24 04:05PM	Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (Business Wire)
Feb-08-24 01:15PM	The 3 Most Undervalued Biotech Stocks to Buy in February 2024 (InvestorPlace)
Jan-30-24 08:48PM	Acadia Announces Additions to Executive Team (Business Wire)
05:00PM	20 Countries With The Highest Number of Drug Trafficking in the World (Insider Monkey)
Jan-26-24 05:31PM	Best Drug and Alcohol Rehab Centers in Each of 30 Biggest Cities in the US (Insider Monkey)
Jan-25-24 08:42AM	10 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts (Insider Monkey)
Jan-19-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Nov 19 '24	Sale	16.81	10,329	173,630	62,105	Nov 19 08:43 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Nov 19 '24	Sale	16.81	4,073	68,467	19,863	Nov 19 08:41 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Nov 19 '24	Sale	16.81	10,259	172,454	53,302	Nov 19 08:40 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Aug 19 '24	Sale	15.28	9,733	148,720	43,735	Aug 20 06:46 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Aug 19 '24	Sale	15.28	9,534	145,680	52,177	Aug 20 06:43 PM
DAVIS STEPHEN	CEO	Aug 19 '24	Sale	15.28	31,747	485,094	186,555	Aug 20 06:40 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Jun 10 '24	Sale	14.79	975	14,420	34,564	Jun 11 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	May 02 '24	Sale	16.94	3,503	59,341	32,053	May 03 06:00 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	May 02 '24	Sale	16.94	3,477	58,900	42,133	May 03 06:00 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	May 02 '24	Sale	16.94	1,326	22,462	14,370	May 03 06:00 PM
DAVIS STEPHEN	CEO	May 02 '24	Sale	16.94	11,427	193,573	155,231	May 03 06:00 PM
DAVIS STEPHEN	CEO	Apr 08 '24	Sale	17.87	26,574	474,877	144,267	Apr 09 06:00 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Apr 08 '24	Sale	17.87	2,568	45,890	38,796	Apr 09 06:00 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Apr 08 '24	Sale	17.87	1,790	31,987	13,100	Apr 09 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Apr 08 '24	Sale	17.87	2,716	48,535	28,742	Apr 09 06:00 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Mar 27 '24	Sale	17.90	5,140	92,006	36,340	Mar 27 08:00 PM
DAVIS STEPHEN	CEO	Mar 27 '24	Sale	17.90	17,714	317,081	118,842	Mar 27 07:58 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Mar 27 '24	Sale	17.90	5,434	97,269	26,183	Mar 27 07:57 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Feb 26 '24	Sale	24.67	772	19,045	21,067	Feb 27 06:13 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Feb 26 '24	Sale	24.67	624	15,394	31,432	Feb 27 06:10 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Feb 26 '24	Sale	24.67	474	11,694	11,391	Feb 27 06:07 PM
DAVIS STEPHEN	CEO	Feb 26 '24	Sale	24.67	5,577	137,585	101,890	Feb 27 06:02 PM
DAVIS STEPHEN	CEO	Jan 08 '24	Sale	29.96	3,732	111,811	96,521	Jan 09 06:00 PM
Teehan Brendan	EVP, COO, Head of Commercial	Jan 08 '24	Sale	29.96	731	21,901	30,949	Jan 09 06:00 PM
KIM AUSTIN D.	EVP,General Counsel, Secretary	Jan 08 '24	Sale	29.96	590	17,676	46,901	Jan 09 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACAD

Acadia Pharmaceuticals Inc

Upgrade your FINVIZ experience